SCIENION and Axxin Jointly Collaborate
News Sep 16, 2015
SCIENION AG and Axxin Pty Ltd. have announced that they have partnered to collaborate on an instrument reader system for the analysis of multiplexed microarrays on lateral flow immunoassay strips.
Lateral flow immunoassays represent popular point of care diagnostics, as they are easy to use, cost-effective and produce rapid results. Both companies, SCIENION and Axxin, take an active part in this market segment and contribute with its technologies towards products and services for its customers.
Joining forces in this field brings together SCIENION’s picoliter dispensing technology and Axxin’s proven track record in commercializing diagnostic instrument systems for point of care diagnostics. The first joint project will be the development of a colorimetric reader system for multiplexed lateral flow microarrays for point of care and R&D applications. Multiplexed lateral flow assays can benefit from a dedicated detection device that provides optimal and quantitative analysis of results that eye-only interpretation could not match.
A series of early field tests with selected beta customers has already been initiated and shows very promising results. Initial applications focus on lateral flow microarrays with the capability of analyzing up to 20 parameters for infectious diseases, drugs of abuse, and allergies.
Holger Eickhoff, CEO of SCIENION, says: “Axxin is a well-known provider of reader platforms and diagnostic products for lateral flow applications. When we met first earlier this year, we immediately anticipated the benefits of a collaboration to generate added value for our customers. Combining our expertise and technologies means leveraging integrated solutions from two ends. Multiplexing is a vital topic in lateral flow point of care diagnostics and I am convinced that our collaboration will result in breakthrough products in an otherwise mature market.”
Axxin CEO Andrew Lysikatos says: “Strategic alliances and collaborations are an important part of Axxin's overall strategy. Axxin is seeking commercial partnerships with leading companies to develop and provide world class low cost point of care platforms to address unmet needs. With SCIENION we found a perfect partner for the production of multiplexed lateral flow assays, as the capabilities of the sciFLEXARRAYER dispensing technology allow for miniaturization, multiplexing and precise spotting of dots and lines in any patterns favored.”
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.
CRISPR Causes More Genome Damage Than First ThoughtNews
Researchers have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.